Nan Zhu, PhD

Publications

• Epigenetic regulation of protein translation in KMT2A-rearranged AML.

  (Lenard A, Xie HM, Pastuer T, Shank T, Libbrecht C, Kingsley M, Riedel SS, Yuan ZF, Zhu N, Neff T, Bernt KM.) Exp Hematol. 2020 May;85:57-69 PMID: 32437908 PMCID: PMC8362846 05/22/2020

• CXCR5+PD-1+ follicular helper CD8 T cells control B cell tolerance.

  (Chen Y, Yu M, Zheng Y, Fu G, Xin G, Zhu W, Luo L, Burns R, Li QZ, Dent AL, Zhu N, Cui W, Malherbe L, Wen R, Wang D.) Nat Commun. 2019 Sep 27;10(1):4415 PMID: 31562329 PMCID: PMC6765049 SCOPUS ID: 2-s2.0-85072692451 09/29/2019

• Critical role of Jumonji domain of JMJD1C in MLL-rearranged leukemia.

  (Izaguirre-Carbonell J, Christiansen L, Burns R, Schmitz J, Li C, Mokry RL, Bluemn T, Zheng Y, Shen J, Carlson KS, Rao S, Wang D, Zhu N.) Blood Adv. 2019 May 14;3(9):1499-1511 PMID: 31076406 PMCID: PMC6517669 SCOPUS ID: 2-s2.0-85068626845 05/12/2019

• Stem cell damage after chemotherapy- can we do better?

  (Tang J, Zhu N, Rao S, Carlson KS.) Best Pract Res Clin Haematol. 2019 Mar;32(1):31-39 PMID: 30927973 SCOPUS ID: 2-s2.0-85061244660 04/01/2019

• Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays.

  (Deshpande A, Chen BR, Zhao L, Saddoris K, Kerr M, Zhu N, Mali P, Deshpande AJ.) J Vis Exp. 2019 Jan 07(143) PMID: 30663717 01/22/2019

• PLCγ-dependent mTOR signalling controls IL-7-mediated early B cell development.

  (Yu M, Chen Y, Zeng H, Zheng Y, Fu G, Zhu W, Broeckel U, Aggarwal P, Turner A, Neale G, Guy C, Zhu N, Chi H, Wen R, Wang D.) Nat Commun. 2017 Nov 13;8(1):1457 PMID: 29133930 PMCID: PMC5684131 SCOPUS ID: 2-s2.0-85034212045 11/15/2017

• Metabolically Derived Lysine Acylations and Neighboring Modifications Tune the Binding of the BET Bromodomains to Histone H4.

  (Olp MD, Zhu N, Smith BC.) Biochemistry. 2017 Oct 17;56(41):5485-5495 PMID: 28945351 PMCID: PMC5970795 09/26/2017

• Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic Leukemia.

  (Danis E, Yamauchi T, Echanique K, Zhang X, Haladyna JN, Riedel SS, Zhu N, Xie H, Orkin SH, Armstrong SA, Bernt KM, Neff T.) Cell Rep. 2016 Mar 01;14(8):1953-65 PMID: 26904942 PMCID: PMC4790111 02/26/2016

• DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.

  (Chen CW, Koche RP, Sinha AU, Deshpande AJ, Zhu N, Eng R, Doench JG, Xu H, Chu SH, Qi J, Wang X, Delaney C, Bernt KM, Root DE, Hahn WC, Bradner JE, Armstrong SA.) Nat Med. 2015 Apr;21(4):335-43 PMID: 25822366 PMCID: PMC4390532 03/31/2015

• AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes.

  (Deshpande AJ, Deshpande A, Sinha AU, Chen L, Chang J, Cihan A, Fazio M, Chen CW, Zhu N, Koche R, Dzhekieva L, Ibáñez G, Dias S, Banka D, Krivtsov A, Luo M, Roeder RG, Bradner JE, Bernt KM, Armstrong SA.) Cancer Cell. 2014 Dec 08;26(6):896-908 PMID: 25464900 PMCID: PMC4291116 12/04/2014

• CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma.

  (Huang CH, Lujambio A, Zuber J, Tschaharganeh DF, Doran MG, Evans MJ, Kitzing T, Zhu N, de Stanchina E, Sawyers CL, Armstrong SA, Lewis JS, Sherr CJ, Lowe SW.) Genes Dev. 2014 Aug 15;28(16):1800-14 PMID: 25128497 PMCID: PMC4197965 08/17/2014

• Notch pathway activation targets AML-initiating cell homeostasis and differentiation.

  (Lobry C, Ntziachristos P, Ndiaye-Lobry D, Oh P, Cimmino L, Zhu N, Araldi E, Hu W, Freund J, Abdel-Wahab O, Ibrahim S, Skokos D, Armstrong SA, Levine RL, Park CY, Aifantis I.) J Exp Med. 2013 Feb 11;210(2):301-19 PMID: 23359070 PMCID: PMC3570103 01/30/2013